BioPharmSignal logoBioPharmSignal

Biotech News

Rani Therapeutics Initiates Phase 1 Study of RT-114 RaniPill® for the Treatment of Obesity in Collaboration with ProGen

Rani Therapeutics (RANI)Rani TherapeuticsClinical readout

- A phase 1 study to evaluate safety, tolerability, bioavailability, pharmacokinetics, and weight loss of GLP-1/GLP-2 dual agonist, PG-102, administered orally via RaniPill ® capsule versus subcutaneous injection - SAN JOSE, Calif., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings,

Related news

RANIRani Therapeutics2026-07-15 12:00 EST

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

RANIRani Therapeutics2026-08-13 20:05 EST

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

View all latest news

Rani Therapeutics

Oral Biologics Delivery Rani Therapeutics develops capsules that deliver biologic drugs through the intestinal wall, seeking to replace injections with oral administration. RaniPill Platform The RaniPill capsule protects its payload during passage through the stomach and deploys a microneedle-like mechanism in the small intestine. The...

Recent company news

RANIRani Therapeutics2026-10-05 12:00 EST

Rani Therapeutics Announces Acceptance into U.S. FDA's Emerging Technology Program (ETP)

RANIRani Therapeutics2026-09-08 12:00 EST

Rani Therapeutics to Participate in Upcoming September Conferences

RANIRani Therapeutics2026-08-13 20:05 EST

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

RANIRani Therapeutics2026-08-10 12:00 EST

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

RANIRani Therapeutics2026-08-04 12:00 EST

Rani Therapeutics Appoints Michelle Gilson to Board of Directors

Stock data

Close
0.83 USD
Market cap
96.4M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States